New ASCIA Clinical Care Standard for inborn errors of immunity / primary immunodeficiencies
A new ASCIA Clinical Care Standard for Inborn Errors of Immunity (IEI)/ Primary Immunodeficiencies (PID) has been developed as part of the ASCIA Immunodeficiency Strategy for Australia and New Zealand in consultation with relevant patient/carer support organisations, AusPIPS, IDFA and IDFNZ,
The main purpose of the ASCIA IEI/PID Clinical Care Standard is to assist in benchmarking and advocating for optimal services and treatment, and to guide resource development and updates.
Minor updates have been made to the following documents, which are linked to in the Clinical Care Standard:
ASCIA Treatment Summary for Patients on Immunoglobulin Therapy (previously called the ASCIA Transfer Care Plan)
ASCIA will also be developing a Clinical Care Standard for hereditary angioedema (HAE) in consultation with the patient/carer support organisation HAE Australasia,
This news item was issued on 5 August 2024 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.